Literature DB >> 26348182

Hormone Use for Therapeutic Amenorrhea and Contraception During Hematopoietic Cell Transplantation.

Katherine Chang1, Melissa A Merideth, Pamela Stratton.   

Abstract

There is a growing population of women who have or will undergo hematopoietic stem cell transplant for a variety of malignant and benign conditions. Gynecologists play an important role in addressing the gynecologic and reproductive health concerns for these women throughout the transplant process. As women undergo cell transplantation, they should avoid becoming pregnant and are at risk of uterine bleeding. Thus, counseling about and implementing hormonal treatments such as gonadotropin-releasing hormone agonists, combined hormonal contraceptives, and progestin-only methods help to achieve therapeutic amenorrhea and can serve as contraception during the peritransplant period. In this commentary, we summarize the timing, risks, and benefits of the hormonal options just before, during, and for the year after hematopoietic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26348182      PMCID: PMC4580508          DOI: 10.1097/AOG.0000000000001031

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

Review 1.  Perspectives on the co-treatment with GnRHa in female patients undergoing hematopoietic stem cell transplantation.

Authors:  Luminita Nicoleta Cima; Anca Colita; Simona Fica
Journal:  Endocr Connect       Date:  2017-09-25       Impact factor: 3.335

Review 2.  Sexual and Emotional Health after Allogeneic Hematopoietic Cell Transplantation: A Comprehensive Review and Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Authors:  Tamim Alsuliman; Ludovic Jondreville; Caroline Baylet; Marie-Pierre Dann; Natacha De Bentzmann; Marie-Laure Fontoura; Carole Genty; Anne Huynh; Diane Ibled; Ibrahim Yakoub-Agha; Lara Mercier; Catherine Poirot; Sophie Porcheron; Catherine Tourette-Turgis; Jean-Paul Vernant; Dominique Vexiau-Robert; Stéphanie Nguyen
Journal:  J Clin Med       Date:  2022-02-23       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.